AVIR Q2 2022 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$32M

Net Income

-$31M

EPS (Diluted)

$-0.38

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$21M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$694M

Total Liabilities

$34M

Stockholders' Equity

$660M

Cash & Equivalents

$684M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$60M	-100.0%
Gross Profit	$0	$21M	-100.0%
Operating Income	-$32M	$9M	-471.8%
Net Income	-$31M	$2M	-2136.1%